Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia
Lando Janssen, Maria T. E. Hopman, Greetje J. A. Swaans, Neeltje A. E. Allard, Marti Boss, Daphne Lobeek, Martin Gotthardt, Tom J.J. Schirris, Nicole M. A. Blijlevens, Silvie Timmers
Abstract
In this study, we have shown that non-diabetic patients with CML receiving nilotinib therapy show early signs of disturbed skeletal muscle glucose handling, which was not observed in imatinib-treated patients. These observations in nilotinib users may reflect decreased muscle insulin sensitivity, which could serve as a potential target to counteract glycemic dysregulation, and is of clinical importance since these patients have an increased cardiovascular disease risk.
Topics & Concepts
NilotinibMedicineMyeloid leukemiaGlycemicTyrosine kinaseTyrosine-kinase inhibitorInternal medicineInsulinImatinibEndocrinologyDiseaseInsulin sensitivitySkeletal muscleOncologyInsulin resistanceCancerReceptorChronic Myeloid Leukemia TreatmentsChemotherapy-induced cardiotoxicity and mitigationHER2/EGFR in Cancer Research